Next Article in Journal
Sarcopenia Prevalence and Risk Factors among Residents in Aged Care
Previous Article in Journal
Cyanidin-3-O-Glucoside Ameliorates Palmitic-Acid-Induced Pancreatic Beta Cell Dysfunction by Modulating CHOP-Mediated Endoplasmic Reticulum Stress Pathways
 
 
Reply published on 28 April 2022, see Nutrients 2022, 14(9), 1848.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Comment

Comment on Suresh et al. The Short-Term Effects and Tolerability of Low-Viscosity Soluble Fibre on Gastroparesis Patients: A Pilot Clinical Intervention Study. Nutrients 2021, 13, 4298

1
Department of Internal Medicine, Jerry M. Wallace School of Osteopathic Medicine, Campbell University, Buies Creek, NC 27546, USA
2
Department of Internal Medicine, McLaren Macomb Hospital, Mt. Clemens, MI 48043, USA
*
Author to whom correspondence should be addressed.
Nutrients 2022, 14(9), 1836; https://doi.org/10.3390/nu14091836
Submission received: 8 February 2022 / Accepted: 14 April 2022 / Published: 28 April 2022
(This article belongs to the Section Clinical Nutrition)
Zhou and colleagues are commended for their innovative research on the tolerability of “low-viscosity” fibre supplements in symptomatic diabetic gastroparesis patients [1]. Using a randomized controlled crossover pilot clinical study design, they demonstrated the beneficial effects of partially hydrolysed guar gum and gum Arabic on blood glucose regulation with no significant adverse gastrointestinal effects, i.e., comparable to negative controls. Their observations are a major step forward in solving the gastroparesis riddle and challenge the broadly held premise that all dietary fibre should be avoided or minimized in these patients [2].
Furthermore, recent reports have found the treatment efficacy of gastric peroral endoscopic myotomy for gastroparesis to substantially diminish over time [3], and the effectiveness in symptom control with gastric electrical stimulation to be also less than ideal [4]. Importantly, other studies have shown intestinal dysmotility and constipation to be widely prevalent among these patients, and their severity also correlates with gastroparesis symptomatology [5,6,7]. Moreover, one intriguing report demonstrated that healthy volunteers could impair gastric emptying by self-induced constipation [8]. Given these studies, the widely accepted hypothesis that gastroparesis is a primary gastric motor disorder must be reconsidered.
Another clue in solving the gastroparesis riddle are the landmark observations by Burkitt and others who correlated low stool weights with impaired intestinal transit times (ITTs) [9]. For instance, United Kingdom Navy personnel consuming the typical Western low-fibre diet had a mean ITT of 83 h and mean daily stool weights of 104 g. In contrast, rural Ugandan villagers consuming their indigenous high fibre diets had a mean ITT of 36 h and mean daily stool weights of 470 g. In essence, their findings suggest that achieving large bulky stools may restore intestinal motility by reducing ITT, and thereby possibly alleviate or even resolve gastroparesis symptoms. As dietary fibre has weak laxative effects, osmotic laxatives are frequently required to achieve and sustain increased stool bulk (clinical observations by corresponding author).
Based upon these reports and our experience [10], we believe that constipation is a frequently overlooked cause of gastroparesis. Provided this hypothesis is correct, then regardless of the therapeutic intervention employed, sustained symptomatic improvement of gastroparesis would only be expected if stool weights exceed two to three hundred grams daily and if ITTs average less than 40 h. Moreover, ITT could be a non-invasive and inexpensive test to assess intestinal motility. Finally, we suggest that future gastroparesis studies consider stool weights and ITTs as possible variables that may impact study outcomes.

Author Contributions

Conceptualization: J.W.J.; Writing—original draft preparation: J.W.J.; Writing—review and editing: J.W.J., K.L., G.D.B. All authors have read and agreed to the published version of the manuscript.

Funding

This report received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Suresh, H.; Zhou, J.; Ho, V. The Short-Term Effects and Tolerability of Low-Viscosity Soluble Fibre on Gastroparesis Patients: A Pilot Clinical Intervention Study. Nutrients 2021, 13, 4298. [Google Scholar] [CrossRef] [PubMed]
  2. Krishnasamy, S.; Abell, T.L. Diabetic Gastroparesis: Principles and Current Trends in Management. Diabetes Ther. 2018, 9 (Suppl. 1), 1–42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Abdelfatah, M.M.; Noll, A.; Kapil, N.; Shah, R.; Li, L.; Nustas, R.; Li, B.; Luo, H.; Chen, H.; Xia, L.; et al. Long-term Outcome of Gastric Per-Oral Endoscopic Pyloromyotomy in Treatment of Gastroparesis. Clin. Gastroenterol. Hepatol. 2021, 19, 816–824. [Google Scholar] [CrossRef] [PubMed]
  4. Shanker, A.; Bashashati, M.; Rezaie, A. Gastric Electrical Stimulation for Treatment of Refractory Gastroparesis: The Current Approach to Management. Curr. Gastroenterol. Rep. 2021, 23, 2. [Google Scholar] [CrossRef] [PubMed]
  5. Sarosiek, I.; Selover, K.H.; Katz, L.A.; Semler, J.R.; Wilding, G.E.; Lackner, J.M.; Sitrin, M.D.; Kuo, B.; Chey, W.D.; Hasler, W.L.; et al. The assessment of regional gut transit times in healthy controls and patients with gastroparesis using wireless motility technology. Aliment. Pharmacol. Ther. 2009, 31, 313–322. [Google Scholar] [CrossRef] [PubMed]
  6. Cogliandro, R.F.; Rizzoli, G.; Bellacosa, L.; de Giorgio, R.; Cremon, C.; Barbara, G.; Stanghellini, V. Is gastroparesis a gastric disease? Neurogastroenterol. Motil. 2019, 31, e13562. [Google Scholar] [CrossRef] [PubMed]
  7. Parkman, H.P.; Sharkey, E.; McCallum, R.W.; Hasler, W.L.; Koch, K.L.; Sarosiek, I.; Abell, T.L.; Kuo, B.; Shulman, R.J.; Grover, M.; et al. Constipation in Patients with Symptoms of Gastroparesis: Analysis of Symptoms and Gastrointestinal Transit. Clin. Gastroenterol. Hepatol. 2020, 20, 546–558.e5. [Google Scholar] [CrossRef] [PubMed]
  8. Burkitt, D.; Walker, A.; Painter, N. Effect of dietary fibre on stools and transit-times, and its role in the causation of disease. Lancet 1972, 300, 1408–1411. [Google Scholar] [CrossRef]
  9. Tjeerdsma, H.C.; Akkermans, L.M.A. Voluntary suppression of defecation delays gastric emptying. Am. J. Dig. Dis. 1993, 38, 832–836. [Google Scholar] [CrossRef] [PubMed]
  10. Jones, J.W.; Lamont, K.L.; Stoltenberg, J.N.; Brannan, G.D. A Low Cost, Novel Treatment of Severe Diabetic Gastroparesis Based on Burkitt’s Dietary Fiber Hypothesis. Cureus 2021, 13, e18062. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Jones, J.W.; Lamont, K.; Brannan, G.D. Comment on Suresh et al. The Short-Term Effects and Tolerability of Low-Viscosity Soluble Fibre on Gastroparesis Patients: A Pilot Clinical Intervention Study. Nutrients 2021, 13, 4298. Nutrients 2022, 14, 1836. https://doi.org/10.3390/nu14091836

AMA Style

Jones JW, Lamont K, Brannan GD. Comment on Suresh et al. The Short-Term Effects and Tolerability of Low-Viscosity Soluble Fibre on Gastroparesis Patients: A Pilot Clinical Intervention Study. Nutrients 2021, 13, 4298. Nutrients. 2022; 14(9):1836. https://doi.org/10.3390/nu14091836

Chicago/Turabian Style

Jones, J. Wesley, Katrina Lamont, and Grace D. Brannan. 2022. "Comment on Suresh et al. The Short-Term Effects and Tolerability of Low-Viscosity Soluble Fibre on Gastroparesis Patients: A Pilot Clinical Intervention Study. Nutrients 2021, 13, 4298" Nutrients 14, no. 9: 1836. https://doi.org/10.3390/nu14091836

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop